Background and aims: There is limited data on IBD patients diagnosed with viral hepatitis B and C. The aim of the study was to assess the prevalence of chronic HBV or HCV infection in IBD patients followed by our centre and to describe and review the course of bowel and liver disease during therapy. Methods: Single centre retrospective study on 482 consecutive IBD patients. Laboratory investigation for HBV and HCV was performed with routine methods. Treatment protocols for HBV included IFNa and nucleot(s)ide administration and for HCV combined IFNa and ribavirin. Results: We diagnosed 15 patients (15/482, 3.1%) with HBV or HCV. Of these, 11 were HBV (11/482, 2.3%) and 4 were HCV (4/482, 0.8%). Nine of eleven HBV patients received antiviral therapy (8 lamivudine, 1 IFNa). Five lamivudine patients were switched to tenofovir and in another one adefovir dipivoxil were added. Bowel disease was in remission in ten of the eleven HBV patients. One patient was diagnosed with carcinoid tumor. Two HCV patients received IFNa that was well tolerated. One HCV patient denied therapy and one died from hepatocellular cancer. Of the seven patients on azathioprine only one achieved sustained response. Four patients on Infliximab achieved bowel disease remission but experienced biochemical or virological flare. Conclusions: This study demonstrates that prevalence of HBV and HCV infection in a large IBD cohort from Western Balkans is compared to that of the background population. IBD patients under immunosuppressants may apparently be treated with safety if preventive antiviral treatment is administered. 
Introduction
Patients with longstanding inflammatory bowel disease (IBD) seem to be at higher risk for hepatitis B (HBV) and hepatitis C virus (HCV) infection compared with the general population because of the need for high-risk procedures such as endoscopy and surgery as well as blood transfusions. 1, 2 According to epidemiological and treatment group studies the cumulative prevalence of either HCV or HBV seem to present a large variance. According to studies from Spain and Italy, the prevalence of HBsAg(+) has been reported to range from 2.7% to 7.5% 3, 4 while the prevalence of HCV(+) has been reported to range from 1.2% to 17.1%. 3, 5 Furthermore, according to a study from south France the prevalence of HCV was higher in Crohn's disease (CD) patients undergoing surgery compared to ulcerative colitis (UC) patients. 6 In addition, according to studies from Italy 4 and Rio de Janeiro 7 anti-HBcore(+) prevalence was higher in IBD patients compared to the control group individuals.
It is remarkable that there is not always agreement among studies. In two recent studies from Spain 8 and France 9 the cumulative prevalence of HBV and HCV infection in IBD patients was similar to that of the general population of reference and was lower compared to previously published series.
HBV or HCV virus in IBD seems to increase patients' morbidity. In an IBD cohort from Stockholm, infections with hepatitis B and C transmitted by blood transfusions accounted for various abnormalities in liver function. 10 In addition, coexistence of HCV and primary sclerosing cholangitis (PSC) and the development of de novo IBD after liver transplantation for acute severe flare of HBV have been also described. 11, 12 Several case studies have reported worsening 2, 5, 13, 14 or onset of IBD 1 while patients are being treated for HCV. On the other hand, the chronic use of immunomodulators to treat IBD could potentially make the HCV worse. It has been suggested that the spectrum and frequency of IFNa toxicity is similar in HCV infected patients with and without IBD 15 and, of interest, IFNa has been proposed as an option for the treatment of steroid-resistant UC but no significant advantage was observed. 16 There is scarce information about the effect of immunomodulatory drugs on the clinical course of liver disease in IBD patients with concomitant HBV or HCV virus infection 17 and several cases of reactivation of HBV infection in IBD patients receiving Infliximab have been reported. 2, 18 The aim of this study was to assess the prevalence of chronic HBV or HCV infection in IBD patients followed by our centre and to describe our experience during therapy and follow up of these patients. In addition, the present article reviews all currently available literature on the topic.
Patients and methods

Referral single centre study
Our department is a national referral centre for IBD with one of the largest outpatient IBD and hepatology clinics in the country and in western Balkans. This department is the only referral centre for IBD therapeutics in Northwest Greece and is currently coordinating clinical observational studies and epidemiological surveys in more than 1000 IBD patients.
For this study we retrospectively analysed the electronic database of our outpatient clinic that is including 482 consecutive patients from the same geographical area (Table 1) . Of these patients 308 were diagnosed with UC (male/female: 173(56%)/135(44%), median age 41.3 years, range 14-79 years), 145 with CD (m/f: 82(56%)/63(44%), median age 38.7 years, range 14-73 years) and 29 with indeterminate colitis (m/f: 18(62%)/11(38%), median age 33.4 years, range 22-43 years). We analysed 453 patients as patients with indeterminate colitis are showing most likely minor risk factors (i.e. surgery).
Prevalence of hepatitis B and C in the area
Northwest Greece has a population of approximately 800,000 inhabitants and represents an area of low hepatitis B prevalence, never exceeding the 3% of the native population. In Greece HBV vaccination in neonates was started on in the early 90s in parallel with screening of all pregnant women, while vaccination in 11 year adolescents started in 1998 with a 90% estimated coverage. HCV prevalence in our area is less that 0.5%. 19 
Hepatological follow up in IBD patients
All IBD patients undergo regular follow up in the out-patient clinic including 6-monthly liver function tests and biannual abdominal ultrasonography in order to better assess IBD behaviour and potential complications. A liver biopsy was suggested to all patients with unexplained transaminase elevations for at least 6-month duration. All HBsAg(+) or HCV(+) patients are followed every three months with liver function tests and every six months with liver ultrasound, afetoprotein and HBV-DNA or HCV-RNA respectively. 
Laboratory investigation for HBV and HCV
Aminotransferase levels, alkaline phosphatase, gamma glutamyl transferase and total bilirubin were measured by standard laboratory methods. Coded serum samples were tested in the laboratory of Immunology of our department for HBV and HCV. Every sample was examined for HBV using routine methods. HBsAg and anti-HBcore IgM and IgG were tested by enzyme-linked immunosorbent assay. Antibodies to HBsAg -3) . HCV-RNA was tested in serum by nested-polymerase chain reaction after reverse transcription (RT-PCR) and quantified by branched-DNA signal amplification assay. HCV genotype-when applicable-was assessed in all HCV-positive patients by analysis of PCR products, carried out with specific DNA probes.
Treatment protocol for HBV therapy
Generally, all patients with HBV infection should be treated when they have both increased liver enzymes and positive HBV-DNA. 20 In addition, in all patients administered corticosteroids or immunomodulators prophylactic HBV treatment should be initiated despite HBV-DNA and transaminase levels. In our series, patients were treated with IFNa administration for 18 months as first choice of therapy in newly diagnosed HBV(+) patients meeting all available inclusion criteria for such therapy. In case of sustained response to IFNa patient is followed every six months.
In case of incomplete or non-response to IFNa patient is administered therapy with nucleot(s)ide analogues and is followed up every three months. In our IBD/HBV(+) patients and in the view of restricted literature on the topic, it was decided to favour therapy with nucleot(s)ide analogues rather than IFNa. Thus, IBD/HBsAg(+) were treated with lamivudine (Zeffix, Glaxo-Welcome, Research Triangle Park, NC) at a dose of 100 mg/d as this was the only therapy available during the previous decade.
On follow up, lamivudine administration was maintained unchanged in patients with normal liver function tests and HBV-DNA serology. In lamivudine-resistant patients therapy with adefovir dipivoxil (Hepsera, Gilead) or tenofovir (Viread, Gilead) was initiated.
Treatment protocol for HCV therapy
In our series, patients were treated with combination of pegylated (PEG)-IFNa and ribavirin as first choice of therapy when IBD/HCV(+)patients were meeting all available inclusion criteria for such therapy. 20 Thus, IBD/HCV(+) patients were accordingly treated (upon availability at the time of treatment initiation) with combination of IFNa 3MUI three times a week (or PEG-IFNa once a week) plus ribavirin. Treatment period is set to 3-18 months according to HCV genotype and early biochemical and virological responses.
Response to treatment
Responses to treatment were classified as previously described 5 : complete response-persistently normal ALT and viral clearance (HBV-DNA or HCV-RNA −ve) at the end of treatment, incomplete response −ALT normalization without viral clearance (HBV-DNA or HCV-RNA +ve), and sustained response-ALT normalization and hepatitis B or C virus clearance 12 months after the end of treatment.
Ethics committee approval
All IBD patients followed by our Department are attending the Northwest Greece IBD registry project. This project has been approved by the ethics Committee of the Ioannina School of Medicine. Therapies administered in our patients were all commercially available.
Statistical analysis
We reported all data as median and range. For all calculations we used the SPSS 16.0 working package (SPSS Inc., Chicago, IL).
Results
Prevalence of HBV and HCV
We diagnosed 15 patients (15/482, 3.1%) with chronic hepatitis B or C. Of these patients 11 were diagnosed with HBV (11/482, 2.3%) and 4 with HCV (4/482, 0.8%). Of note, four patients (4/ 15, 26.6%) were unaware of their hepatitis until IBD diagnosis. Follow up (median-range) was 11.6 (2-32) years for IBD and 13.4 (2-30) years for hepatitis. The clinical parameters and case analysis are presented in Tables 2 and 3 respectively.
Results of HBV therapy
Of the 11 IBD patients diagnosed with HBV, five were on 5-ASA, two on 5-ASA and azathioprine and five on azathioprine. On follow up three azathioprine-treated patients were switched to Infliximab.
Four patients with HBV before IBD diagnosis received the first choice therapy with IFNa-when available-for 18 months when criteria for therapy were fulfilled. On follow up, they were switched to lamivudine-when it was available-either because of an HBV flare (HBV-DNA or transaminase elevation) or because of IBD diagnosis and subsequent treatment. In one patient on low dose 5-ASA with HBV prior to IBD diagnosis and with bowel and liver disease long-term remission, therapy for HBV was not initiated.
Patients with HBV diagnosis concomitant to IBD or after IBD diagnosis received prophylactic lamivudine (4 patients) or IFNa (1 patient). In one patient on low dose 5-ASA with HBV concomitant to IBD diagnosis and bowel and liver disease quiescent phase, therapy for HBV was not initiated.
In total, nine of the eleven HBV patients received continuous antiviral therapy (8 lamivudine, 1 IFNa) either as prophylaxis (5 patients) or as continuing HBV therapy preceding IBD diagnosis (4 patients).
Continuous lamivudine was administered for 4.9 years (range 2-9 years). On follow up, only two of the eight patients on lamivudine had sustained response. In the remaining six, after the third year of therapy and due to incomplete response 5 lamivudine patients were switched to tenofovir and in one lamivudine patient adefovir dipivoxil was added. Patient on IFNa achieved sustained response and the two untreated Table 6 Clinical outcomes in patients diagnosed or/and treated for hepatitis C, inflammatory bowel disease and other autoimmune diseases. [Abbreviations used in the Table: IBD =  inflammatory patients remained at a quiescent phase with all tests at within normal limits. Bowel disease was in remission in ten of the eleven patients. The eleventh patient, who was a 47-year-old male diagnosed with CD ileocolitis and treated with azathioprine for two years was diagnosed with small bowel carcinoid and was successfully operated. No patient had exacerbation of the IBD related to HBV therapy.
Results of HCV therapy
Of the four IBD patients diagnosed with HCV one patient was on 5-ASA, one on azathioprine, one on Infliximab and one permanent ileostomy patient received no treatment.
Two of the four HCV patients received antiviral therapy, IFNa 3MUI three times a week that was available at that period. Both patients were genotype 1a and received 18-month treatment, which was tolerated well. From the two remaining patients, both genotype 3, the first was an alcohol abuser and denied IFNa therapy while the other did not tolerate IFNa therapy and died 12 years after his hepatitis diagnosis from hepatocellular cancer.
Bowel disease was in remission in three of the four patients; one patient underwent total colectomy and permanent ileostomy prior to IFNa initiation so we cannot conclude on his IBD course during IFNa treatment.
Effect of azathioprine and Infliximab on HBV and HCV
In our IBD cohort 135 (135/482, 28%) patients (107 CD, 28 UC) are treated with thiopurines and 48 (48/482, 9.9%) patients are treated with Infliximab. The prevalence of HBV infection in patients treated or not with thiopurines was 7/135 (5.1%) and 4/347 (1.1%) respectively. The prevalence of HBV infection in patients treated or not with Infliximab was 4/ 48 (8.3%) and 7/434 (1.6%) respectively. It should be noticed herein that 3 of the 4 HBV patients on Infliximab were previously on azathioprine.
The prevalence of HCV infection in patients treated or not with thiopurines was 1/135 (0.7%) and 3/347(0.9%) respectively. The prevalence of HCV infection in patients treated or not with Infliximab was 1/48(2%) and 3/434 (0.7%) respectively.
In total 7/15 patients (six HBV, one HCV) received azathioprine. All six patients with HBV received continuous azathioprine at a dose of 2 mg/Kg for a median period of 7 years (range 2-16 years). Three of those six patients were treated with azathioprine before any administration of preventive antiviral treatment was possible. In two patients we observed a continuous low-increased HBV-DNA (up to 1200 c/μl) with normal transaminases and in one patient we observed transient ALT elevations that never exceeded two times upper the normal limit. Only one of three azathioprine-HBV patients achieved sustained biochemical and virological responses.
One 85-year-old HCV patient diagnosed with left-sided UC and treated with azathioprine for five years was diagnosed with hepatocellular cancer and died six months after diagnosis.
On follow up, 4/15 patients (3 HBV, one HCV) received Infliximab induction and then maintenance scheme at a dose of 5 mg/Kg for a median period of 2 years (range 1-6 years).
Three patients were switched to Infliximab after azathioprine discontinuation and one patient received Infliximab monotherapy as initial treatment. Those patients were 3 males (aged 48, 53 and 62 years, two diagnosed with UC pancolitis and one with CD ileocolitis) and one 42-year old, left-sided UC female. All patients achieved with Infliximab remission in their bowel disease but experienced either biochemical (2 HBV, 1 HCV) or virological flare (1 HBV patient). All flares occurred during the first year of Infliximab infusions (approximately at eight infusions) and were asymptomatic with no further complications. Flares had a mild course regarding biochemical and virological parameters. In all three HBV patients lamivudine was switched to tenofovir and for the HCV patient we started on ursodeoxycholic acid.
Discussion
In this study we present our experience on the largest group of IBD patients with chronic HBV or HCV infection and antiviral therapy in Greece and in Western Balkans. In addition, we review all currently available literature on this topic.
Despite the limitations of its retrospective nature this is the first systematic attempt to describe the true dimensions of the problem in this area of major public health interest due to rapid political and demographic changes and the high rate of immigration of young population groups. Regional or global European policy on health care and prevention of transmittable diseases resides a lot in the information of such epidemiological studies. Along these lines health care consumption in chronic diseases is important for every country to further design health policy and health care priorities.
The prevalence of HBV and HCV in our IBD group of patients is 2.3% and 0.8% respectively and parallels that of the background population as it was observed in a study from Spain 8 and France 9 ( Table 4) . [3] [4] [5] [6] [7] [8] [9] This HBV and HCV prevalence reported herein is of the lowest ever reported in similar IBD studies and although limited data is available, our results are comparable to those reported from Italy 4 and Brasil 7 for HBV and from Spain 3 for HCV. Possible characteristics of our study population, as also the relatively low number of CD patients could be possible explanation for discrepant findings when compared with previous studies.
In IBD patients infected with HBV we favoured nucleot(s)ide therapy rather than IFNa due to the limited and conflicting data concerning a possible influence of IFNa on IBD relapse (Table 5) . 3, 12, 18, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The majority of the patients initially responding to lamivudine had to be switched to combination therapy either with adefovir dipivoxil or tenofovir due to biochemical or/and virological relapse.
Exacerbation of UC by the treatment with interferon for chronic hepatitis B has been reported. 36, 37 Of note, the only HBV patient receiving IFNa did well. All data herein is discussed with reservations 33, 38 as the activity of the disease was in remission at the time of clinical record review but it may be deduced that these patients had flares of the disease or chronic continuous inflammation because they needed chronic administration of immunosuppressants for disease control.
From the two patients with the difficult-to-treat HCV1a genotype one patient responded well but we cannot conclude for the effect of INFa to his bowel as he was colectomized on beforehand. An association between interferon therapy and the onset or flares of IBD has been described in HCV infected individuals (Table 6) . 1, 2, 11, 14, 17, However, in these two HCV patients we did not observe flares of IBD during IFN therapy and we tend to support like others 5, 13, 15, 44 that IFN does not appear to worsen the course of established IBD in patients already on maintenance IBD therapy. Of note, a study showed that gastrointestinal symptoms may be temporarily exacerbated and haematopoietic growth factors may be required. 2 By contrast, an interferon-beta-has induced remission of UC in a patient with HCV 39 and IFN has been used in therapeutic trials in IBD (Table 7) . 2, 5, 15, 16, [60] [61] [62] It should be stressed herein that the experience using IFNa in this study is very limited to drawn conclusions. However do not suggest a bad influence on IBD outcome.
Attempting a critical review of the available literature in order to provide a possible explanation for the differences observed between studies showing a negative effect of IFNa on IBD activity and no effect in others we could briefly comment the following; IFNa is generally safe when IBD is in remission and cautious administration of concomitant to IFNa treatment is important. However, some UC patients may present an unpredictable acute flare shortly after IFNa initiation and this is probably related to individual immune factors.
Although we did not face difficult-to-treat HCV patients 27 it has been suggested that treatment of HCV is feasible in the presence of Infliximab. 40 Immunomodulatory drugs such as azathioprine and methotrexate may increase hepatitis B and C viremia and reduce ALT levels, related to an increased intracellular viral replication. 24, 61 We observed, like others 13, 35 , that immunomodulatory drugs appear not to influence the course of hepatic virus or acute flares. 63, 64 Infliximab use is safe in general 65, 66 but in patients with HBV has been so far reported only in 19 patients (16 with IBD) including our 3 cases (Table 8) . 3, 17, 18, [21] [22] [23] [24] [25] [26] 28, 29, 31, 32, 35, 40, 46, 50, 54 The use of Infliximab appears safe in HBV patients with prophylaxis, that is, initiation of antiviral therapy possibly 4 weeks prior to anti-TNFa therapy and early intervention with frequent monitoring of HBV-DNA levels and liver enzymes to allow early detection and treatment. 22, 67 Subfulminant hepatitis B 24 , occult hepatitis B and Infliximab-induced HBV reactivation have been reported 21, 23, 29 , and even after a single infusion. 25 We have administered lamivudine prophylaxis in all our three patients as this was for many years the only available safe, well tolerated, and effective in preventing HBV reactivation nucleotide. However, in most of the patients we experienced lamivudine resistance 3 or/and Infliximab-induced flare and we switched to tenofovir. In fact, long-term therapy with lamivudine has been shown to induce resistance in the form of mutations in the Tyr-Met-Asp-Asp locus and between 16% and 32% of patients develop the YMDD mutation after 1 year of lamivudine therapy. 3, 68 In our centre screening for hepatitis B and C and HIV as well as hepatitis B vaccination is routinely performed in all IBD patients.
Immunomodulatory drugs probably influence the course of HBV and HCV and may be dangerous if antivirals are not administered. Of interest, none of the patients in this study received combined immunosuppression. This is important since opportunistic infections in general reactivate in patients receiving two or more immunosuppressants. In this study severe acute flares were not observed probably due to the administration of preventive antiviral treatment.
Infliximab use in patients with HCV has been so far reported in 13 patients (10 with IBD) including our single case ( Table 8) . Based on the available data, it appears that TNFa antagonists have no adverse hepatic effects on patients with HCV. A mild elevation in liver function tests as happened in our case needs to be cautiously interpreted and careful follow up is mandatory. 13, 46, 54 One of our patients was an alcohol abuser but none of the others was co-diagnosed with non-alcoholic fatty liver disease or steatohepatitis that may increase the vulnerability of the liver to HBV or HCV chronic infection. 69, 70 In conclusion, this study demonstrated that prevalence of chronic hepatitis B and hepatitis C infection in a large IBD cohort from Western Balkans is compared to that of the background population. IBD patients under immunosuppressants may apparently be treated with safety if preventive antiviral treatment is administered.
